Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic Disease

Autores
Marchini, Timoteo Oscar; Malchow, Sara; Caceres, Lourdes; El Rabih, Abed Al Hadi; Hansen, Sophie; Mwinyella, Timothy; Spiga, Lisa; Piepenburg, Sven; Horstmann, Hauke; Olawale, Tijani; Li, Xiaowei; Mitre, Lucia Sol; Gissler, Mark Colin; Bugger, Heiko; Zirlik, Andreas; Heidt, Timo; Hilgendorf, Ingo; Stachon, Peter; von zur Muehlen, Constantin; Bode, Christoph; Wolf, Dennis
Año de publicación
2022
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Rationale: Atherosclerosis is a chronic inflammatory disease of large arteries that involves an autoimmune response with autoreactive T cells and auto-antibodies recognizing Apolipoprotein B (ApoB), the core protein of low-density lipoprotein (LDL). Here, we aimed to establish a clinical association between circulating human ApoB auto-antibodies with atherosclerosis and its clinical risk factors using a novel assay to detect auto-antibodies against a pool of highly immunogenic ApoB-peptides. Methods and Results: To detect polyclonal IgM- and IgG-antibodies recognizing ApoB, we developed a chemiluminescent sandwich ELISA with 30 ApoB peptides selected by an in silico assay for a high binding affinity to MHC-II, which cover more than 80% of known MHC-II variants in a Caucasian population. This pre-selection of immunogenic self-peptides accounted for the high variability of human MHC-II, which is fundamental to allow T cell dependent generation of IgG antibodies. We quantified levels of ApoB-autoantibodies in a clinical cohort of 307 patients that underwent coronary angiography. Plasma anti-ApoB IgG and IgM concentrations showed no differences across healthy individuals (n = 67), patients with coronary artery disease (n = 179), and patients with an acute coronary syndrome (n = 61). However, plasma levels of anti-ApoB IgG, which are considered pro-inflammatory, were significantly increased in patients with obesity (p = 0.044) and arterial hypertension (p < 0.0001). In addition, patients diagnosed with the metabolic syndrome showed significantly elevated Anti-ApoB IgG (p = 0.002). Even when normalized for total plasma IgG, anti-ApoB IgG remained highly upregulated in hypertensive patients (p < 0.0001). We observed no association with triglycerides, total cholesterol, VLDL, or LDL plasma levels. However, total and normalized anti-ApoB IgG levels negatively correlated with HDL. In contrast, total and normalized anti-ApoB IgM, that have been suggested as anti-inflammatory, were significantly lower in diabetic patients (p = 0.012) and in patients with the metabolic syndrome (p = 0.005). Conclusion: Using a novel ELISA method to detect auto-antibodies against ApoB in humans, we show that anti-ApoB IgG associate with cardiovascular risk factors but not with the clinical appearance of atherosclerosis, suggesting that humoral immune responses against ApoB are shaped by cardiovascular risk factors but not disease status itself. This novel tool will be helpful to develop immune-based risk stratification for clinical atherosclerosis in the future.
Fil: Marchini, Timoteo Oscar. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Bioquímica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de Bioquímica y Medicina Molecular; Argentina. Albert Ludwigs University of Freiburg; Alemania
Fil: Malchow, Sara. Albert Ludwigs University of Freiburg; Alemania
Fil: Caceres, Lourdes. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Bioquímica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de Bioquímica y Medicina Molecular; Argentina. Albert Ludwigs University of Freiburg; Alemania
Fil: El Rabih, Abed Al Hadi. Albert Ludwigs University of Freiburg; Alemania
Fil: Hansen, Sophie. Albert Ludwigs University of Freiburg; Alemania
Fil: Mwinyella, Timothy. Albert Ludwigs University of Freiburg; Alemania
Fil: Spiga, Lisa. Albert Ludwigs University of Freiburg; Alemania
Fil: Piepenburg, Sven. Albert Ludwigs University of Freiburg; Alemania
Fil: Horstmann, Hauke. Albert Ludwigs University of Freiburg; Alemania
Fil: Olawale, Tijani. Albert Ludwigs University of Freiburg; Alemania
Fil: Li, Xiaowei. Albert Ludwigs University of Freiburg; Alemania
Fil: Mitre, Lucia Sol. Albert Ludwigs University of Freiburg; Alemania
Fil: Gissler, Mark Colin. Albert Ludwigs University of Freiburg; Alemania
Fil: Bugger, Heiko. University of Graz; Austria
Fil: Zirlik, Andreas. University of Graz; Austria
Fil: Heidt, Timo. Albert Ludwigs University of Freiburg; Alemania
Fil: Hilgendorf, Ingo. Albert Ludwigs University of Freiburg; Alemania
Fil: Stachon, Peter. Albert Ludwigs University of Freiburg; Alemania
Fil: von zur Muehlen, Constantin. Albert Ludwigs University of Freiburg; Alemania
Fil: Bode, Christoph. Albert Ludwigs University of Freiburg; Alemania
Fil: Wolf, Dennis. Albert Ludwigs University of Freiburg; Alemania
Materia
APOB
ATHEROSCLEROSIS
AUTO-ANTIBODIES
CARDIOVASCULAR DISEASE
IMMUNITY
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/204732

id CONICETDig_90484e853cdd0ff39b12ea7398c7bba4
oai_identifier_str oai:ri.conicet.gov.ar:11336/204732
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic DiseaseMarchini, Timoteo OscarMalchow, SaraCaceres, LourdesEl Rabih, Abed Al HadiHansen, SophieMwinyella, TimothySpiga, LisaPiepenburg, SvenHorstmann, HaukeOlawale, TijaniLi, XiaoweiMitre, Lucia SolGissler, Mark ColinBugger, HeikoZirlik, AndreasHeidt, TimoHilgendorf, IngoStachon, Petervon zur Muehlen, ConstantinBode, ChristophWolf, DennisAPOBATHEROSCLEROSISAUTO-ANTIBODIESCARDIOVASCULAR DISEASEIMMUNITYhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Rationale: Atherosclerosis is a chronic inflammatory disease of large arteries that involves an autoimmune response with autoreactive T cells and auto-antibodies recognizing Apolipoprotein B (ApoB), the core protein of low-density lipoprotein (LDL). Here, we aimed to establish a clinical association between circulating human ApoB auto-antibodies with atherosclerosis and its clinical risk factors using a novel assay to detect auto-antibodies against a pool of highly immunogenic ApoB-peptides. Methods and Results: To detect polyclonal IgM- and IgG-antibodies recognizing ApoB, we developed a chemiluminescent sandwich ELISA with 30 ApoB peptides selected by an in silico assay for a high binding affinity to MHC-II, which cover more than 80% of known MHC-II variants in a Caucasian population. This pre-selection of immunogenic self-peptides accounted for the high variability of human MHC-II, which is fundamental to allow T cell dependent generation of IgG antibodies. We quantified levels of ApoB-autoantibodies in a clinical cohort of 307 patients that underwent coronary angiography. Plasma anti-ApoB IgG and IgM concentrations showed no differences across healthy individuals (n = 67), patients with coronary artery disease (n = 179), and patients with an acute coronary syndrome (n = 61). However, plasma levels of anti-ApoB IgG, which are considered pro-inflammatory, were significantly increased in patients with obesity (p = 0.044) and arterial hypertension (p < 0.0001). In addition, patients diagnosed with the metabolic syndrome showed significantly elevated Anti-ApoB IgG (p = 0.002). Even when normalized for total plasma IgG, anti-ApoB IgG remained highly upregulated in hypertensive patients (p < 0.0001). We observed no association with triglycerides, total cholesterol, VLDL, or LDL plasma levels. However, total and normalized anti-ApoB IgG levels negatively correlated with HDL. In contrast, total and normalized anti-ApoB IgM, that have been suggested as anti-inflammatory, were significantly lower in diabetic patients (p = 0.012) and in patients with the metabolic syndrome (p = 0.005). Conclusion: Using a novel ELISA method to detect auto-antibodies against ApoB in humans, we show that anti-ApoB IgG associate with cardiovascular risk factors but not with the clinical appearance of atherosclerosis, suggesting that humoral immune responses against ApoB are shaped by cardiovascular risk factors but not disease status itself. This novel tool will be helpful to develop immune-based risk stratification for clinical atherosclerosis in the future.Fil: Marchini, Timoteo Oscar. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Bioquímica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de Bioquímica y Medicina Molecular; Argentina. Albert Ludwigs University of Freiburg; AlemaniaFil: Malchow, Sara. Albert Ludwigs University of Freiburg; AlemaniaFil: Caceres, Lourdes. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Bioquímica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de Bioquímica y Medicina Molecular; Argentina. Albert Ludwigs University of Freiburg; AlemaniaFil: El Rabih, Abed Al Hadi. Albert Ludwigs University of Freiburg; AlemaniaFil: Hansen, Sophie. Albert Ludwigs University of Freiburg; AlemaniaFil: Mwinyella, Timothy. Albert Ludwigs University of Freiburg; AlemaniaFil: Spiga, Lisa. Albert Ludwigs University of Freiburg; AlemaniaFil: Piepenburg, Sven. Albert Ludwigs University of Freiburg; AlemaniaFil: Horstmann, Hauke. Albert Ludwigs University of Freiburg; AlemaniaFil: Olawale, Tijani. Albert Ludwigs University of Freiburg; AlemaniaFil: Li, Xiaowei. Albert Ludwigs University of Freiburg; AlemaniaFil: Mitre, Lucia Sol. Albert Ludwigs University of Freiburg; AlemaniaFil: Gissler, Mark Colin. Albert Ludwigs University of Freiburg; AlemaniaFil: Bugger, Heiko. University of Graz; AustriaFil: Zirlik, Andreas. University of Graz; AustriaFil: Heidt, Timo. Albert Ludwigs University of Freiburg; AlemaniaFil: Hilgendorf, Ingo. Albert Ludwigs University of Freiburg; AlemaniaFil: Stachon, Peter. Albert Ludwigs University of Freiburg; AlemaniaFil: von zur Muehlen, Constantin. Albert Ludwigs University of Freiburg; AlemaniaFil: Bode, Christoph. Albert Ludwigs University of Freiburg; AlemaniaFil: Wolf, Dennis. Albert Ludwigs University of Freiburg; AlemaniaFrontiers Media2022-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/204732Marchini, Timoteo Oscar; Malchow, Sara; Caceres, Lourdes; El Rabih, Abed Al Hadi; Hansen, Sophie; et al.; Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic Disease; Frontiers Media; Frontiers in Cardiovascular Medicine; 9; 4-2022; 1-112297-055XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fcvm.2022.826729/fullinfo:eu-repo/semantics/altIdentifier/doi/10.3389/fcvm.2022.826729info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:45:01Zoai:ri.conicet.gov.ar:11336/204732instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:45:01.622CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic Disease
title Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic Disease
spellingShingle Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic Disease
Marchini, Timoteo Oscar
APOB
ATHEROSCLEROSIS
AUTO-ANTIBODIES
CARDIOVASCULAR DISEASE
IMMUNITY
title_short Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic Disease
title_full Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic Disease
title_fullStr Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic Disease
title_full_unstemmed Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic Disease
title_sort Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic Disease
dc.creator.none.fl_str_mv Marchini, Timoteo Oscar
Malchow, Sara
Caceres, Lourdes
El Rabih, Abed Al Hadi
Hansen, Sophie
Mwinyella, Timothy
Spiga, Lisa
Piepenburg, Sven
Horstmann, Hauke
Olawale, Tijani
Li, Xiaowei
Mitre, Lucia Sol
Gissler, Mark Colin
Bugger, Heiko
Zirlik, Andreas
Heidt, Timo
Hilgendorf, Ingo
Stachon, Peter
von zur Muehlen, Constantin
Bode, Christoph
Wolf, Dennis
author Marchini, Timoteo Oscar
author_facet Marchini, Timoteo Oscar
Malchow, Sara
Caceres, Lourdes
El Rabih, Abed Al Hadi
Hansen, Sophie
Mwinyella, Timothy
Spiga, Lisa
Piepenburg, Sven
Horstmann, Hauke
Olawale, Tijani
Li, Xiaowei
Mitre, Lucia Sol
Gissler, Mark Colin
Bugger, Heiko
Zirlik, Andreas
Heidt, Timo
Hilgendorf, Ingo
Stachon, Peter
von zur Muehlen, Constantin
Bode, Christoph
Wolf, Dennis
author_role author
author2 Malchow, Sara
Caceres, Lourdes
El Rabih, Abed Al Hadi
Hansen, Sophie
Mwinyella, Timothy
Spiga, Lisa
Piepenburg, Sven
Horstmann, Hauke
Olawale, Tijani
Li, Xiaowei
Mitre, Lucia Sol
Gissler, Mark Colin
Bugger, Heiko
Zirlik, Andreas
Heidt, Timo
Hilgendorf, Ingo
Stachon, Peter
von zur Muehlen, Constantin
Bode, Christoph
Wolf, Dennis
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv APOB
ATHEROSCLEROSIS
AUTO-ANTIBODIES
CARDIOVASCULAR DISEASE
IMMUNITY
topic APOB
ATHEROSCLEROSIS
AUTO-ANTIBODIES
CARDIOVASCULAR DISEASE
IMMUNITY
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Rationale: Atherosclerosis is a chronic inflammatory disease of large arteries that involves an autoimmune response with autoreactive T cells and auto-antibodies recognizing Apolipoprotein B (ApoB), the core protein of low-density lipoprotein (LDL). Here, we aimed to establish a clinical association between circulating human ApoB auto-antibodies with atherosclerosis and its clinical risk factors using a novel assay to detect auto-antibodies against a pool of highly immunogenic ApoB-peptides. Methods and Results: To detect polyclonal IgM- and IgG-antibodies recognizing ApoB, we developed a chemiluminescent sandwich ELISA with 30 ApoB peptides selected by an in silico assay for a high binding affinity to MHC-II, which cover more than 80% of known MHC-II variants in a Caucasian population. This pre-selection of immunogenic self-peptides accounted for the high variability of human MHC-II, which is fundamental to allow T cell dependent generation of IgG antibodies. We quantified levels of ApoB-autoantibodies in a clinical cohort of 307 patients that underwent coronary angiography. Plasma anti-ApoB IgG and IgM concentrations showed no differences across healthy individuals (n = 67), patients with coronary artery disease (n = 179), and patients with an acute coronary syndrome (n = 61). However, plasma levels of anti-ApoB IgG, which are considered pro-inflammatory, were significantly increased in patients with obesity (p = 0.044) and arterial hypertension (p < 0.0001). In addition, patients diagnosed with the metabolic syndrome showed significantly elevated Anti-ApoB IgG (p = 0.002). Even when normalized for total plasma IgG, anti-ApoB IgG remained highly upregulated in hypertensive patients (p < 0.0001). We observed no association with triglycerides, total cholesterol, VLDL, or LDL plasma levels. However, total and normalized anti-ApoB IgG levels negatively correlated with HDL. In contrast, total and normalized anti-ApoB IgM, that have been suggested as anti-inflammatory, were significantly lower in diabetic patients (p = 0.012) and in patients with the metabolic syndrome (p = 0.005). Conclusion: Using a novel ELISA method to detect auto-antibodies against ApoB in humans, we show that anti-ApoB IgG associate with cardiovascular risk factors but not with the clinical appearance of atherosclerosis, suggesting that humoral immune responses against ApoB are shaped by cardiovascular risk factors but not disease status itself. This novel tool will be helpful to develop immune-based risk stratification for clinical atherosclerosis in the future.
Fil: Marchini, Timoteo Oscar. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Bioquímica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de Bioquímica y Medicina Molecular; Argentina. Albert Ludwigs University of Freiburg; Alemania
Fil: Malchow, Sara. Albert Ludwigs University of Freiburg; Alemania
Fil: Caceres, Lourdes. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Bioquímica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de Bioquímica y Medicina Molecular; Argentina. Albert Ludwigs University of Freiburg; Alemania
Fil: El Rabih, Abed Al Hadi. Albert Ludwigs University of Freiburg; Alemania
Fil: Hansen, Sophie. Albert Ludwigs University of Freiburg; Alemania
Fil: Mwinyella, Timothy. Albert Ludwigs University of Freiburg; Alemania
Fil: Spiga, Lisa. Albert Ludwigs University of Freiburg; Alemania
Fil: Piepenburg, Sven. Albert Ludwigs University of Freiburg; Alemania
Fil: Horstmann, Hauke. Albert Ludwigs University of Freiburg; Alemania
Fil: Olawale, Tijani. Albert Ludwigs University of Freiburg; Alemania
Fil: Li, Xiaowei. Albert Ludwigs University of Freiburg; Alemania
Fil: Mitre, Lucia Sol. Albert Ludwigs University of Freiburg; Alemania
Fil: Gissler, Mark Colin. Albert Ludwigs University of Freiburg; Alemania
Fil: Bugger, Heiko. University of Graz; Austria
Fil: Zirlik, Andreas. University of Graz; Austria
Fil: Heidt, Timo. Albert Ludwigs University of Freiburg; Alemania
Fil: Hilgendorf, Ingo. Albert Ludwigs University of Freiburg; Alemania
Fil: Stachon, Peter. Albert Ludwigs University of Freiburg; Alemania
Fil: von zur Muehlen, Constantin. Albert Ludwigs University of Freiburg; Alemania
Fil: Bode, Christoph. Albert Ludwigs University of Freiburg; Alemania
Fil: Wolf, Dennis. Albert Ludwigs University of Freiburg; Alemania
description Rationale: Atherosclerosis is a chronic inflammatory disease of large arteries that involves an autoimmune response with autoreactive T cells and auto-antibodies recognizing Apolipoprotein B (ApoB), the core protein of low-density lipoprotein (LDL). Here, we aimed to establish a clinical association between circulating human ApoB auto-antibodies with atherosclerosis and its clinical risk factors using a novel assay to detect auto-antibodies against a pool of highly immunogenic ApoB-peptides. Methods and Results: To detect polyclonal IgM- and IgG-antibodies recognizing ApoB, we developed a chemiluminescent sandwich ELISA with 30 ApoB peptides selected by an in silico assay for a high binding affinity to MHC-II, which cover more than 80% of known MHC-II variants in a Caucasian population. This pre-selection of immunogenic self-peptides accounted for the high variability of human MHC-II, which is fundamental to allow T cell dependent generation of IgG antibodies. We quantified levels of ApoB-autoantibodies in a clinical cohort of 307 patients that underwent coronary angiography. Plasma anti-ApoB IgG and IgM concentrations showed no differences across healthy individuals (n = 67), patients with coronary artery disease (n = 179), and patients with an acute coronary syndrome (n = 61). However, plasma levels of anti-ApoB IgG, which are considered pro-inflammatory, were significantly increased in patients with obesity (p = 0.044) and arterial hypertension (p < 0.0001). In addition, patients diagnosed with the metabolic syndrome showed significantly elevated Anti-ApoB IgG (p = 0.002). Even when normalized for total plasma IgG, anti-ApoB IgG remained highly upregulated in hypertensive patients (p < 0.0001). We observed no association with triglycerides, total cholesterol, VLDL, or LDL plasma levels. However, total and normalized anti-ApoB IgG levels negatively correlated with HDL. In contrast, total and normalized anti-ApoB IgM, that have been suggested as anti-inflammatory, were significantly lower in diabetic patients (p = 0.012) and in patients with the metabolic syndrome (p = 0.005). Conclusion: Using a novel ELISA method to detect auto-antibodies against ApoB in humans, we show that anti-ApoB IgG associate with cardiovascular risk factors but not with the clinical appearance of atherosclerosis, suggesting that humoral immune responses against ApoB are shaped by cardiovascular risk factors but not disease status itself. This novel tool will be helpful to develop immune-based risk stratification for clinical atherosclerosis in the future.
publishDate 2022
dc.date.none.fl_str_mv 2022-04
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/204732
Marchini, Timoteo Oscar; Malchow, Sara; Caceres, Lourdes; El Rabih, Abed Al Hadi; Hansen, Sophie; et al.; Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic Disease; Frontiers Media; Frontiers in Cardiovascular Medicine; 9; 4-2022; 1-11
2297-055X
CONICET Digital
CONICET
url http://hdl.handle.net/11336/204732
identifier_str_mv Marchini, Timoteo Oscar; Malchow, Sara; Caceres, Lourdes; El Rabih, Abed Al Hadi; Hansen, Sophie; et al.; Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic Disease; Frontiers Media; Frontiers in Cardiovascular Medicine; 9; 4-2022; 1-11
2297-055X
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fcvm.2022.826729/full
info:eu-repo/semantics/altIdentifier/doi/10.3389/fcvm.2022.826729
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Frontiers Media
publisher.none.fl_str_mv Frontiers Media
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842268704326287360
score 13.13397